In last trading session, Homology Medicines Inc. (NASDAQ:FIXX) saw 0.31 million shares changing hands with its beta currently measuring -0.60. Company’s recent per share price level of $3.69 trading at $0.04 or 1.10% at ring of the bell on the day assigns it a market valuation of $213.25M. That closing price of FIXX’s stock is at a discount of -313.01% from its 52-week high price of $15.24 and is indicating a premium of 8.67% from its 52-week low price of $3.37. Taking a look at company’s average trading volume of 413.70K if we extend that period to 3-months.
For Homology Medicines Inc. (FIXX), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.60. Splitting up the data highlights that, out of 10 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.58 in the current quarter.
Homology Medicines Inc. (NASDAQ:FIXX) trade information
Upright in the green during last session for gaining 1.10%, in the last five days FIXX remained trading in the green while hitting it’s week-highest on Thursday, 01/13/22 when the stock touched $3.69 price level, adding 5.38% to its value on the day. Homology Medicines Inc.’s shares saw a change of 1.37% in year-to-date performance and have moved 5.73% in past 5-day. Homology Medicines Inc. (NASDAQ:FIXX) showed a performance of -13.58% in past 30-days.
Wall Street analysts have assigned a consensus price target of $23.33 to the stock, which implies a rise of 84.18% to its current value. Analysts have been projecting $8.00 as a low price target for the stock while placing it at a high target of $35.00. It follows that stock’s current price would drop -848.51% in reaching the projected high whereas dropping to the targeted low would mean a loss of -116.8% for stock’s current value.
Homology Medicines Inc. (FIXX) estimates and forecasts
Statistics highlight that Homology Medicines Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -41.61% of value to its shares in past 6 months, showing an annual growth rate of 38.57% while that of industry is 5.00. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 6.50% in the current quarter and calculating -2,850.00% decrease in the next quarter. This year revenue growth is estimated to rise 1,148.00% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $710k for the same. And 5 analysts are in estimates of company making revenue of $1 million in the next quarter that will end on Mar 2022. Company posted $980k and $29.3 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -27.60% while estimating it to be -96.60% for the next quarter.
In 2022, company’s earnings growth rate is likely to be around -13.60% while estimates for its earnings growth in next 5 years are of -9.40%.
Homology Medicines Inc. is more likely to be releasing its next quarterly report between March 09 and March 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Homology Medicines Inc. (NASDAQ:FIXX)’s Major holders
Insiders are in possession of 9.13% of company’s total shares while institution are holding 67.19 percent of that, with stock having share float percentage of 73.94%. Investors also watch the number of corporate investors in a company very closely, which is 67.19% institutions for Homology Medicines Inc. that are currently holding shares of the company. Temasek Holdings (Private) Limited is the top institutional holder at FIXX for having 5.65 million shares of worth $44.47 million. And as of Sep 29, 2021, it was holding 9.89% of the company’s outstanding shares.
The second largest institutional holder is 5AM Venture Management, LLC, which was holding about 4.54 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 7.94% of outstanding shares, having a total worth of $35.7 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) New Horizons Fund are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 1.25 million shares of worth $7.18 million or 2.19% of the total outstanding shares. The later fund manager was in possession of 1.24 million shares on Sep 29, 2021, making its stake of worth around $9.75 million in the company or a holder of 2.17% of company’s stock.